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ABSTRACT
Objectives: To optimize, apply, and validate a scoring algorithm that
provides a utility index from a cancer-speciﬁc quality of life questionnaire
called the Utility-Based Questionnaire-Cancer (UBQ-C) using data sets
from randomized trials in breast cancer. The index is designed to reﬂect the
perspective of cancer patients in a speciﬁc clinical context so as to best
inform clinical decisions.
Methods: We applied the UBQ-C scoring algorithm to trials of chemo-
therapy for advanced (n = 325) and early (n = 126) breast cancer. The
algorithm converts UBQ-C subscales into a subset index, and combines it
with a global health status item into an overall HRQL index, which is then
converted to a utility index using a power transformation. The optimal
subscale weights were determined by their correlations with the global
scale in the relevant data set. The validity of the utility index was tested
against other patient characteristics.
Results: Optimal weights (range 0–1) for the subset index in advanced
(early) breast cancer were: physical function 0.20 (0.09); social/usual
activities 0.23 (0.25); self-care 0.04 (0.01); and distresses 0.53 (0.64).
Weights for the overall HRQL index were health status 0.66 (0.63) and
subset index 0.34 (0.37). The utility index discriminated between breast
cancer that was advanced rather than early (means 0.88 vs. 0.94,
P < 0.0001) and was responsive to the toxic effects of chemotherapy in
early breast cancer (mean change 0.07, P < 0.0001).
Conclusions: The scoring algorithm for the UBQ-C utility index can be
optimized in different clinical contexts to reﬂect the relative importance of
different aspects of quality of life to the patients in a trial. It can be used
to generate sensitive and responsive utility scores, and quality-adjusted
life-years that can be used within a trial to compare the net beneﬁt of
treatments and inform clinical decision-making.
Keywords: cancer, health-state utility, health-related quality of life,
patient-derived preferences.
Introduction
The quality-adjusted life-year (QALY) approach is a useful way
to compare cancer treatments, because it integrates the beneﬁcial
and harmful effects of treatment on health-related quality of life
(HRQL), expressed as a utility, with the effects of treatment on
survival [1–3]. Analyses of cancer trials in terms of utilities and
QALYs are increasingly used to inform economic decisions about
cancer treatments [4–10], but can also be used to inform clinical
decisions [11–16].
A practical and feasible approach to obtain utility scores for
generating QALYs in cancer trials is to use a utility-based instru-
ment. A utility-based instrument uses a scoring algorithm to
convert the responses from a questionnaire that elicits ratings
about various dimensions of HRQL to a utility index [1,17,18].
The scoring algorithm is valued in a valuation survey, where a
sample of people directly assign a utility score to the health states
described by the questionnaire using a time trade-off interview or
related technique [19]. A utility-based instrument may include
generic or disease-speciﬁc questions, and the scoring algorithm
may generate utilities that are based on the perspective of lay
people or patients. Three of the most commonly used instru-
ments are the EuroQol EQ-5D [20], Health Utilities Index
(HUI3) [21], and the Short Form 6D (SF-6D) [22]. These
instruments include generic questions applicable to any disease
or population, and their scoring algorithms are based on the
perspective of lay people. Utility-based instruments reported
more recently have included disease-speciﬁc questions and use
scoring algorithms that are based on the perspective of patients
rather than lay people [23–25].
Ideally, the perspective from which a utility instrument is
valued should reﬂect the views of the population that the
researcher is trying to reﬂect in the decision-making [1,17,26,27].
In a companion paper we emphasized that patients typically
assign a higher utility to a health state than a lay person, which
can have signiﬁcant implications for health funding, policy, and
clinical decisions that incorporate utilities and QALYs [23].
Researchers using utilities to inform health funding and policy
decisions will generally prefer the perspective of lay people
[28–30], whereas researchers using utilities to inform clinical
decisions will generally prefer the perspective of patients
[1,17,26,31,32]. This is because the objective of clinical decisions
is to maximize health for an individual patient with that disease
[23]. Recently, it has been recognized that the preferences and
attitudes of lay people in different countries may differ, because
of differences in demographic background, social and cultural
values, and political and economic systems [33,34]. As a result,
some scoring algorithms for utility-based instruments based on
the perspective of lay people have been optimized for use in
different countries to reﬂect these differences [33,35–37]. It has
also been recognized that the preferences and attitudes of cancer
patients in different clinical contexts may differ, because patients
with different cancer diagnoses, stages of disease, and treatment
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may assign different importance to different aspects of HRQL
[38–41]. We posit that scoring algorithms for utility-based instru-
ments based on the perspective of patients should be optimized
for different treatment contexts to reﬂect these differences.
Lumley et al. have developed a novel approach to optimizing
scoring algorithms for different clinical contexts using the HRQL
data collected in that context [38]. Lumley’s approach requires a
questionnaire including items about the speciﬁc aspects of HRQL
and a single-item global scale. We deﬁne a single-item global scale
as one asking respondents directly for a uniﬁed assessment of
their HRQL. Lumley’s approach gives extra weight to the
responses about speciﬁc aspects of HRQL that are more highly
correlated with the responses on the global scale. These weights
are intended to reﬂect the relative importance that the subjects
assign to different aspects of HRQL. The optimization of the
scoring algorithm requires weighting to be determined for each
clinical context but does not require the valuation survey to be
repeated.
The aim of this work was to use Lumley’s approach to derive
an optimized scoring algorithm for a cancer-speciﬁc HRQL
instrument that is based on the perspective of cancer patients. In
a companion paper we described the development and prelimi-
nary validation of the algorithm [23]. This paper describes the
application of the algorithm to trial data sets, and illustrates how
it can be optimized in different treatment contexts.
Methods
Sources of Data
The data used to optimize, apply, and validate the scoring algo-
rithm were collected in two randomized clinical trials of chemo-
therapy for breast cancer. Both studies were approved by the
human research ethics committees at all participating institu-
tions. All patients provided written informed consent.
The ﬁrst trial, referred to as the “advanced cancer trial,” was
conducted by the Australian New Zealand Breast Cancer Trials
Group. It included patients with advanced breast cancer who
were randomly allocated to receive either daily oral capecitabine
or standard CMF as ﬁrst-line chemotherapy until disease pro-
gression [42]. The primary outcome measure of the trial was
quality-adjusted time to progression. Secondary outcome mea-
sures were time to progression, response rates, HRQL, overall
survival, safety, and cost-effectiveness. Eligible subjects were 18
years or older, and were about to start ﬁrst-line chemotherapy for
histologically conﬁrmed advanced breast cancer. Subjects were
excluded if they were totally conﬁned to bed and completely
disabled [Eastern Cooperative Oncology Group (ECOG) perfor-
mance status 4, as described in the next section]. Enrolment was
from June 2001 to July 2005 at 34 centers in Australia and New
Zealand. Subjects completed the Utility-Based Questionnaire-
Cancer (UBQ-C) and other questionnaires about HRQL that are
described in the following discussion (unless they could not read
English). The data described in this paper came from baseline
questionnaires competed before randomization.
The second trial, referred to as the “early cancer trial,” was
conducted by the Australian New Zealand Breast Cancer Trials
Group in collaboration with the International Breast Cancer
Study Group. It included patients with high-risk early stage
breast cancer who were randomly allocated to receive either
high-dose chemotherapy with stem cell support more than 12
weeks or standard-dose chemotherapy more than 24 weeks [43].
The primary outcome measure of the trial was overall survival.
Secondary outcome measures were quality-adjusted survival,
disease-free survival, toxicity, HRQL, and cost-effectiveness. Eli-
gible subjects were aged 16 to 65 years, and were about to start
adjuvant chemotherapy for histologically conﬁrmed early-stage
primary breast cancer with ﬁve or more involved axillary nodes.
Subjects were excluded if they were capable of only limited
self-care and/or were conﬁned to a bed or chair for more than
50% of waking hours (ECOG performance status 3 or 4). Enrol-
ment was fromMarch 1997 until March 2000 at multiple centers
in Australia, New Zealand, Europe, and Asia. Subjects living in
Australia and New Zealand were eligible to participate in a
substudy. Substudy participants were required to provide
detailed information about HRQL and resource usage by com-
pleting the UBQ-C and other questionnaires described in the
following discussion. Questionnaires were completed before
starting chemotherapy (baseline), 12 weeks after randomization
(during chemotherapy), and a few months after completing
chemotherapy.
Questionnaires and Other Characteristics of Subjects
The UBQ-C is a validated cancer-speciﬁc questionnaire that was
designed as an outcome measure for clinical trials in the ﬁeld of
cancer. It includes 29 items about speciﬁc aspects of HRQL, and
a single-item global scale that asks respondents to rate their
global health status (health status thermometer) [23,44,45]. The
29 items about speciﬁc aspects of HRQL are grouped into sub-
scales for physical function (three items), social/usual activities
(four items), self-care (one item), and distresses (21 items) caused
by physical and psychological symptoms relevant to cancer and
its treatment. The UBQ-C also includes the general health item
from the SF-36 health survey [46]. More details about the con-
ceptual framework, development, composition, and psychomet-
ric properties of the UBQ-C are given in a companion paper [23].
Two additional questionnaires were completed. The Spitzer
uniscale of global life quality was completed by all subjects as an
additional global scale, but with the anchors of “highest quality”
and “lowest quality” replaced by “best possible” and “worst
possible” [47,48]. The Priestman and Baum linear analog self-
assessment scales (LASAS) were completed by subjects in the
advanced trial as validated measures of cancer-speciﬁc HRQL
that include ﬁve scales about physical well-being, mood, pain,
nausea and vomiting, and appetite [49,50]. Clinicians completed
the ECOG performance status scale in the advanced trial. This
rates patients’ physical functional status as: “0”—fully active;
“1”—restricted in physical activity but able to do light work;
“2”—conﬁned to a bed or chair for less than 50% of waking
hours and capable of all self-care but unable to do any work;
“3”—conﬁned to a bed or chair for more than 50% of waking
hours but capable of limited self-care; and “4”—totally conﬁned
to bed or chair, completely disabled, incapable of any self-care
[51].
Statistical Methods
We optimized the scoring algorithm described in detail in a
companion paper [23] and applied it to the clinical trial data sets.
The scoring algorithm is outlined in Fig. 1.
First, we calculated subscale scores for physical function,
social/usual activities, self-care, and distresses as the simple
average of the nonmissing items, linearly transformed to a scale
from 0 (worst) to 1 (best).
Indices were then calculated by applying the following
formulae:
Subset index = ×[ ] + ×[ ] + ×[ ] + ×[ ]W PF W SA W SC W DI1 2 3 4
(1)
W T r T MSE R= ( ) × − ( )[ ] ( )Var 1 (2)
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Overall HRQL index subset index= ×[ ] + −( ) ×[ ]W W HST1 (3)
Utility index overall HRQL index= − −( )1 1 2 03. (4)
W1 to W4 are the weights for the subscales, PF is physical
function, SA is social/usual activities, SC is self-care, DI is dis-
tresses, and HST is the health status thermometer. W is the
weight allocated to the subset index, so 1 - W is the weight
allocated to the health status thermometer. Var(T) is the variance
of the health status thermometer obtained from the data set. r(T)
is the intraclass correlation coefﬁcient of the health status ther-
mometer, and was calculated with test–retest data from a previ-
ous validation study [45]. MSE(R) is the mean square for error
from the linear regression of the health status thermometer on
the four subscales, and was obtained from the data set.
Optimal weights for the subscales (W1-W4), subset index
(W), and health status thermometer (1 - W) were derived for
each trial using the ratings on the UBQ-C in the relevant data set.
Weights W1 to W4 were derived from and proportional to the
coefﬁcients obtained from multivariable, ordinary least squares
regression of the health status thermometer on the subscales.
Weights W and (1 - W) were derived using Eq. 2.
The weights were then applied using Eqs. 1, 3, and 4 to
calculate scores for the subset index, overall HRQL index, and
utility index for each subject in each trial.
We examined the validity of the utility index against other
characteristics of subjects. We tested its convergent validity, dis-
criminative validity, responsiveness, and predictive validity by
comparing it with other self-rated measures of HRQL and with
measures of physical function, cancer stage, treatment phase, and
subsequent survival.
Convergent validity tests how closely a measure is associated
with related measures [52,53]. The convergent validity of the
utility index was tested by Spearman rank correlation (rS) with
the Spitzer uniscale, the SF-36 general health item, and scales
from the Priestman and Baum LASAS questionnaire referred to
above. We expected substantial correlations with the Spitzer
uniscale and the SF-36 general health item. Three clinical experts
made a priori hypothesis about the expected values of rS with the
LASAS scales as: insigniﬁcant (<0.3), moderate (0.3–0.44), sub-
stantial (0.45–0.59), or high (>0.6). Hypotheses were considered
supported by the data if the observed rS were at least as high as
the median of the experts’ expected rS.
Discriminative validity tests how well a measure can distin-
guish between groups deﬁned by an alternate criterion [53,54].
The discriminative validity of the utility index was tested by its
ability to detect cross-sectional differences between subjects with
differing physical function as rated by their clinicians on the
ECOG performance status scale referred to earlier. We also com-
pared the discriminative ability of the UBQ-C overall HRQL
index with that of the health status thermometer and the Spitzer-
uniscale. Differences between groups were evaluated with Stu-
dents t test.
Responsiveness tests the ability of a measure to detect clini-
cally important change over time [54,55]. The responsiveness of
the utility index was tested by comparing scores in the early
cancer trial before, during, and after chemotherapy using paired
t tests.
Predictive validity tests how closely a measure is associated
with a subsequent outcome [52,53]. The predictive validity of the
utility index was tested by its ability to predict survival duration
in the advanced cancer trial, based on the hypothesis that overall
survival in advanced cancer should be associated with baseline
HRQL [56–60]. The strength of association between the utility
index and survival duration was tested with the log-rank test, by
dichotomizing subjects into a “poor HRQL” group (utility index
less than or equal to the median) and a “good HRQL” group
(utility index greater than the median).
The optimized scoring algorithm was applied to inform a
speciﬁc treatment comparison of high-dose versus standard-dose
chemotherapy for high-risk, early-stage breast cancer using the
data collected during chemotherapy from the early cancer trial.
First, we compared scores on the utility index for participants
allocated to each treatment arm using unpaired t tests. Second,
we used the index to reﬂect the relative importance of the effects
of chemotherapy on different aspects of HRQL by comparing the
weights allocated to each subscale. Third, we tested the hypoth-
esis that the overall HRQL index compared with the health
Overall
HRQL index
1-W
W1
W3
W1-4:
Weights of each subscale
determined by strength of association of
subscale with health status thermometer
Health status
thermometer
Physical
function
1 item
3 items
1 item
UBQ-C global scale
Subset
Index
W
1-W & W:
Weights of health status thermometer
and subset index are proportional
to their statistical precision
Social/usual
activities
Self-care
Distresses
4 items
21 items
W2
W4
Utility index
Transform
UBQ-C subscales
Figure 1 Deriving the overall HRQL index and
utility index from the UBQ-C health-related
quality of life questionnaire. HRQL, health-related
quality of life; UBQ-C, Utility-Based
Questionnaire-Cancer.
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status thermometer would give an estimate of the difference in
mean scores between treatment groups that was more precise but
unbiased. The relative precisions of the related measures were
compared using a measure called the relative efﬁciency statistic
[55,61]. The reciprocal of the relative efﬁciency statistic is the
factor by which the sample size can be reduced when a more
precise and therefore more efﬁcient scale is used. The relative
efﬁciency statistic was calculated as the squared ratio of the
t-score for the index when comparing groups divided by the
t-score for the related global measure when comparing groups.
Results
Study Proﬁles and Patient Characteristics
The study proﬁles describing the subjects in each trial are shown
in Fig. 2. For the advanced cancer trial, compliance was excellent
344 patients in a randomised trial of
b
adjuvant chemotherapy for high-risk
early-stage breast cancer
136 patients eligible to participate in Australia-
New Zealand substudyabout HRQL
208 patients not eligible as recruited outside 
Australia and New Zealand
126 patients agreed to participate 10 patients did not participate 
91 completed questionnaires
prior to chemotherapy
51 completed questionnaires
during chemotherapy
111 completed questionnaires
after completing chemotherapy
325 patients in a randomised trial 
a
of first-line chemotherapy for 
advanced breast cancer
Questionnaires expected from
311 patients at baseline
14 patients unable to
read English
Questionnaires received
from 295 patients at baseline
Questionnaires not received
from 16 patients at baseline
Figure 2 Study proﬁle for (a) advanced and (b)
early cancer trial.
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with questionnaires completed by 95% of subjects who were
expected to complete them. For the early cancer trial, compliance
was not as good with questionnaires completed by 72% before
chemotherapy, 40% during chemotherapy, and 88% after com-
pleting it. All items on each UBQ-C questionnaire except for
“Sex life” and “Other problems” were completed by more than
90% of subjects in both trials. Characteristics of the 421 patients
are shown in Table 1. Data was obtained from patients with
breast cancer of both early and advanced stages. All subjects
were female and most age groups were represented. For the
advanced cancer trial, most had good performance status (ECOG
0 in 34% and ECOG 1 in 54%), and fewer had poor perfor-
mance status (ECOG 2 in 11% and ECOG 3 in 2%). Ratings of
general health ranged from “Excellent” to “Poor.”
Subjects’ ratings on the UBQ-C are summarized in Table 2. At
baseline, patients with advanced cancer reported worse health
status than patients with early cancer as expected [means of 0.69
vs. 0.81, difference 0.13 (with rounding), 95% CI 0.08 to 0.17,
P < 0.0001]. Patients with early cancer reported worse health
status during chemotherapy than before starting it [means 0.68
vs. 0.81, mean deterioration 0.13, 95% conﬁdence internal (CI)
0.08 to 0.19, P < 0.0001]; or after ﬁnishing it [means 0.68 vs.
0.84, mean improvement 0.15 (with rounding), 95% CI 0.10 to
0.21, P < 0.0001]. Similar differences were reported for ratings
on UBQ-C subscales (Table 2).
Optimized Scoring Algorithms
The optimized index weights for the subset index (W), health
status thermometer (1-W), and subscales (W1-4) for each trial
are shown in Table 3. The weight assigned to the health status
thermometer was similar for each trial and accounts for about
two-thirds of the overall HRQL index. Of the subscales, greatest
weight was given to distresses and least to self-care. The ordering
of the weights assigned to the advanced cancer trial and early
cancer trial were similar. Distresses were assigned the greatest
weight, followed by social/usual activities, physical function, and
self-care. However greater weight was assigned to distresses, and
less weight to physical function and self-care, in women with
early breast cancer than in women with advanced cancer.
Validation
Comparisons of the utility index with other characteristics of
subjects supported its validity.
The convergent validity of the utility index was supported by
its substantial correlation with the SF-36 general health item in
both trials (rS 0.74 in advanced and 0.64 in early) and the Spitzer
uniscale in advanced cancer (rS 0.71). There was also complete
concordance of all expected and observed correlations of the
utility index with the Priestman and Baum LASAS in the
advanced cancer trial (data not shown).
The discriminative validity of the utility index was supported
by strong evidence that subjects with early breast cancer before
starting chemotherapy had higher utilities than those with
advanced breast cancer [mean difference 0.07 (with rounding),
95% CI 0.04 to 0.10, P < 0.0001] (Table 2). The discriminative
validity of the utility index was also supported by its ability to
distinguish subjects with differing performance status (PS) as
rated by their clinicians in the advanced cancer trial (good per-
formance status: mean 0.90, 95% CI 0.88 to 0.91; poor perfor-
mance status: mean 0.73, 95% CI 0.67 to 0.79; mean difference
0.17, 95% CI 0.12 to 0.21; P < 0.0001).
The responsiveness of the utility index was supported by
strong evidence that subjects with early breast cancer had higher
utilities before starting chemotherapy than during it (mean dif-
ference 0.07, 95% CI 0.04 to 0.10; P < 0.0001) (Table 2).
The predictive validity of the utility index was supported by
its ability to predict survival duration in the advanced cancer trial
Table 1 Patient characteristics
Data set
Advanced cancer
trial (n = 325)
Early cancer trial
(n = 126)
Cancer stage Advanced High-risk early-stage
Cancer type (%)
Breast 100 100
Gender (%)
Female 100 100
Age (years) (%)
<40 2 14
40–49 12 47
50–59 29 35
60–69 36 3
70 21 —
Data set
Advanced
cancer trial Early cancer trial
Treatment phase Before
treatment
(n = 295)
Before
treatment
(n = 91)
During
treatment
(n = 51)
After
treatment
(n = 111)
General health (%)
Excellent 6 22 6 22
Very good* 18 — — —
Good 30 54 40 66
Fair 32 19 42 9
Poor 13 4 12 3
Response category “Very good” not included in some versions of “General health” item of
the Utility-Based Questionnaire-Cancer.
Table 2 Ratings on the health status thermometer, UBQ-C subscales, overall HRQL index, and utility index
Data set
Advanced cancer trial Early cancer trial
Treatment phase
Before treatment Before treatment During treatment After treatment
Mean SD Mean SD Mean SD Mean SD
Health status thermometer 0.69 0.20 0.81 0.15 0.68 0.21 0.84 0.13
UBQ-C subscales
Physical function 0.53 0.32 0.77 0.21 0.63 0.24 0.80 0.20
Social/usual activities 0.66 0.29 0.74 0.23 0.69 0.22 0.88 0.17
Self-care 0.89 0.20 0.89 0.15 0.97 0.10 0.99 0.06
Distresses 0.78 0.15 0.77 0.15 0.69 0.18 0.83 0.13
Overall HRQL index 0.69 0.18 0.80 0.13 0.68 0.18 0.84 0.12
Utility index 0.88 0.13 0.94 0.07 0.87 0.15 0.96 0.06
All ratings on scale from best (one) to worst (zero).
HRQL, health-related quality of life; SD, standard deviation; UBQ-C, Utility-Based Questionnaire-Cancer.
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when patients were divided into roughly equal-sized groups
above and below the median score on the utility index (Fig. 3).
There was strong evidence that subjects with worse scores on
the utility index at baseline (<0.92) had shorter survival than
those with higher scores (median 17 vs. 23 months, log-rank
P = 0.005).
Treatment Comparison
The scoring algorithm was applied to the treatment comparison
of high-dose chemotherapy versus standard-dose chemotherapy
for early-stage breast cancer. Subjects receiving high-dose chemo-
therapy reported worse impairment of most speciﬁc aspects of
HRQL (Fig. 4), which was expected because high-dose chemo-
therapy is more toxic in this setting [43]. There was a trend to
better mean scores on the utility index for patients allocated to
standard-dose chemotherapy (mean 0.95) compared with high-
dose chemotherapy (mean 0.92) with mean difference of -0.03
(95% CI -0.07 to 0.01, P = 0.10). The overall HRQL index gave
stronger evidence of this effect (mean difference -0.07, 95% CI
-0.13 to -0.01, t = 2.36, P = 0.02) than the health status ther-
mometer (mean difference -0.06, 95% CI -0.12 to 0.01,
t = 1.72, P = 0.09) (Fig. 4). The relative efﬁciency of the overall
HRQL index compared with the health status thermometer was
1.9. In this practical illustration, the improvement in precision by
using the overall HRQL index compared with the health status
thermometer was sufﬁcient to conclude that the more toxic
regimen causes signiﬁcantly worse effects on overall HRQL.
Conclusions
We have applied a scoring algorithm for a cancer-speciﬁc utility-
based instrument to clinical trial data sets and illustrated how it
can be optimized in different clinical contexts. The algorithm
converts ratings from a cancer-speciﬁc questionnaire for HRQL
into a utility index that is based on the perspective of cancer
patients. First, we optimized the scoring algorithm in two differ-
ent clinical contexts for breast cancer by adjusting the index
weights using data from two clinical trials. Second, we applied
the algorithm to generate utility scores. Third, we showed that
the utility index had convergent validity with related scales from
other instruments, discriminative validity between participants
with differing performance status, responsiveness to toxic effects
of chemotherapy in early cancer, and predictive validity about
subsequent survival duration. Fourth, we used the utility index to
inform a treatment comparison of high-dose chemotherapy with
stem-cell support versus standard-dose chemotherapy for high-
risk, early-stage breast cancer. It can be used to generate sensitive
and responsive utility scores, and quality-adjusted life-years that
can be used within a trial to compare the net beneﬁt of treatments
and inform clinical decision-making.
The novelty of the approach described in this paper is that the
scoring algorithm can be optimized for different clinical contexts.
In contrast, most scoring algorithms for utility-based instruments
use the same scoring algorithm across different diseases and
treatments [1,17,20–22]. The algorithm is optimized by giving
additional weight to the subscales about speciﬁc aspects of
HRQL that are most closely associated with a single-item global
scale (the health status thermometer) in the relevant data set. The
reason to optimize the algorithm in different contexts is to reﬂect
variations in patients’ attitudes, preferences, and priorities across
different cancer types, stages, and treatments [38,39].
The primary beneﬁt of optimizing the scoring algorithm for
each clinical context is that it should better reﬂect the perspective
of the individuals in that situation. For example, in the compari-
son of high-dose versus standard-dose chemotherapy for early-
stage breast cancer (Fig. 3), there were large differences in
distresses and physical function but little or no difference in
self-care. Combinations of the subscales giving greater weight to
self-care would yield little difference between high-dose and
standard-dose chemotherapy, whereas those giving greater
weight to distresses and physical function would favor standard-
dose chemotherapy. We assigned weight according to correla-
tions with the health status thermometer, resulting in signiﬁcant
differences between treatments on the indices for overall HRQL
and utility that should reﬂect the preferences and attitudes of the
women in the trial.
Optimizing the scoring algorithm could give more precise
estimates of clinically important differences in utility between
patient groups, because the index is focussed on those aspects of
HRQL that are most relevant to those patients. A more precise
utility index will reduce the uncertainty around the incremental
effectiveness of treatments in sensitivity analyses, because it is
more responsive to small but meaningful effects of cancer treat-
ments [62]. A more precise utility index will also reduce the
sample size required to detect a given difference with a given level
of precision [62].
Another beneﬁt of optimizing the scoring algorithm for each
clinical context is that the ordering of the weights can inform
clinicians and researchers about the importance of various symp-
toms, side effects, and dysfunctions that patients in different
clinical contexts most wish to avoid. For example, in both data
sets we found that greatest weight was given to distresses, fol-
lowed by social/usual activities, physical function, and self-care
(Table 3). The ordering of the weights assigned to each subscale
may be related to several factors. The large weight assigned to
distresses may reﬂect the emotional distress that most patients
experienced caused by having cancer, the physical symptoms of
Table 3 Weights for the health status thermometer and subscales
Advanced
cancer trial
Early
cancer trial
W1 Physical function 0.20 0.09
W2 Social/usual activities 0.23 0.25
W3 Self-care 0.04 0.01
W4 Distresses 0.53 0.64
1-W Health status thermometer 0.66 0.63
W Subset index 0.34 0.37
1-W, W, W1-4 refer to the weights assigned to the health status thermometer, subset index,
and subscales in Eqs. 1 and 2 (see discussion and Figure 1).
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Figure 3 Kaplan–Meier plots for survival duration of subjects grouped by
utility index in advanced cancer trial. Good health-related quality of life
(HRQL), score on utility index <0.92. Poor HRQL, score on utility index0.92.
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advanced cancer, and the side effects of toxic chemotherapy for
early-stage cancer. The low weight assigned to self-care may
reﬂect the lack of problems with self-care that most patients
reported in each trial. The ordering of the weights may also
reﬂect the number of items within each subscale, with distresses
(21 items) assigned greater weight than physical function (three
items), social/usual activities (four items), or self-care (one item).
There were some differences in weights between data sets.
Greater weight was assigned to distresses and less weight was
assigned to physical function for early cancer compared with
advanced cancer (Table 3). The greater weight assigned to dis-
tresses for patients with early cancer may reﬂect their greater
emotional distress caused by a recent diagnosis of cancer, and
their experience of side effects from chemotherapy that had not
yet been administered to the patients with advanced cancer. The
lower weight assigned to physical function for patients with early
cancer is probably explained by the absence of the deterioration
in physical function that occurs with advanced cancer. This infor-
mation can be used by researchers to design more targeted inter-
ventions to improve HRQL in the dimensions of greatest
importance to patients, and by all health-care workers to
improve counselling of patients [39].
We recommend that the scoring algorithm is optimized for
each clinical context in which it is used. This is a potential
limitation in that it requires additional analyses and familiarity
with Lumley’s method. Another limitation is that the utility
scores may not be comparable from one disease or treatment
context to another, because the scoring algorithm and its index
weights cannot be standardized across trials [38]. Consequently
we recommend that our approach is used to compare treatments
in the context of a trial in a well-deﬁned population for a speciﬁc
clinical condition, because the attitudes of patients are likely to
be more similar. It is less suited to studies that include diverse
populations, or for comparing utilities and quality-adjusted life-
years from one study or context to another, because the attitudes
of patients will be more diverse. Comparability of utility scores is
Overall HRQL index
Health status 
thermometer
Distresses
Self-care
Social/usual activities
Physical function
UBQ-C SUBSCALES
Sleeping problems
Nausea
Fatigue
Pain
Concern about 
appearance
Dependence on others
Problems with 
chemotherapy
Lack of concentration
SELECTED UBQ-C 
ITEMS
Measures of global
health status and
overall HRQL
Utility index
-0.40 -0.30 -0.20 -0.10 0.00 0.10
Difference in HRQL
<- Favors standard dose                                      Favors high dose ->
Relative
efficiency
of overall
HRQL index
= 1.9
Figure 4 Differences in HRQL between treat-
ment groups for subjects during treatment in early
cancer trial, based on: 1) selected UBQ-C items; 2)
UBQ-C subscales; 3) health status thermometer;
4) overall HRQL index; and 5) utility index. All
ratings on scale from 0 to 1. HRQL, health-related
quality of life.
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a key requirement when utilities are used to inform economic
decisions, because health funders and policy makers make deci-
sions across diseases and contexts [1,63]. However, comparabil-
ity of utility scores is less important when utilities are used to
inform clinical decisions, because a clinical decision is always
limited to a single disease type and stage. The requirements of
utility scores used to inform clinical decisions are that they reﬂect
the experiences of the patients under study, and are valid, sensi-
tive, and reliable.
The measurement properties of the utility index reported in
this paper support its validity as a measure of HRQL for the
clinical context of chemotherapy for early and advanced breast
cancer. The utility index had convergent validity with indepen-
dent scales of general health and global quality of life, was able
to discriminate patients with different stages of cancer, and was
responsive to changes attributable to having chemotherapy.
Another way to validate a utility index is to compare the scores
derived by the utility index with utilities elicited directly from the
same patients with a time trade-off interview. This could be
performed in future studies.
Future research is also needed to determine if optimization of
the scoring algorithm for each context makes a meaningful dif-
ference to the utility scores and QALYs generated from the utility
index, their sensitivity and responsiveness to detect differences
between treatment groups, and most importantly to the outcome
of clinical decisions in speciﬁc clinical contexts.
Finally, it is important to comment on the strengths and
limitations of the data sets used in this study. Patients participat-
ing in a clinical trial of treatments are the ideal source of infor-
mation about the effects of those treatments on HRQL. The data
sets included patients with early and advanced cancer, before,
during, and after chemotherapy. Compliance was good with the
questionnaire completion, particularly for the advanced cancer
trial. We used validated cancer-speciﬁc questionnaires that
included a broad range of items about speciﬁc aspects of HRQL
that are commonly affected by cancer and side effects of treat-
ment. A limitation of the data sets is that they only included
women in Australia and New Zealand with breast cancer receiv-
ing chemotherapy, so the results may not be applicable to other
cancer types or treatments, other countries, and men. Further
application and validation of the utility index is ongoing in other
clinical contexts including chemotherapy for advanced colorectal
cancer and hormonal therapy for the prevention of breast cancer
[64,65]. The colorectal study includes British and male subjects.
Compliance with completing questionnaires in the early cancer
trial was poor during chemotherapy. Patients who do not com-
plete questionnaires tend to have worse HRQL [66], so the
analyses may underestimate the detrimental effects of treatment
on HRQL. Finally, the early cancer trial is relatively old so the
effects of chemotherapy may be different to that with more
modern treatments. Therefore the utility scores generated from it
may not be appropriate for informing clinical or health policy
decisions about current treatments.
Our approach enables HRQL data obtained with a simple
questionnaire to be converted into utility scores by using an
optimized scoring algorithm that reﬂects the perspective of the
cancer patients under study. The approach is ﬂexible and appli-
cable to other trials and other HRQL instruments. Generation of
utility scores based on HRQL data collected within a clinical trial
provides an ideal source of information to inform clinical deci-
sions, and to add a useful additional perspective to inform health
policy and economic decisions.
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